Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields

British Journal of Cancer

Volumn 105, Issue 5, 2011, Pages 640-648

  Costa, F P ^a   De Oliveira, A C ^a   Meirelles, R ^a   MacHado, M C C ^a   Zanesco, T ^a   Surjan, R ^a   Chammas, M C ^a   De Souza Rocha, M ^a   Morgan, D ^b   Cantor, A ^c   Zimmerman, J ^d   Brezovich, I ^e   Kuster, N ^f   Barbault, A ^g   Pasche, B ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d Heerskink School of Medicine   (United States)

^e The University of Alabama at Birmingham   (United States)

^f FOUNDATION FOR RESEARCH ON INFORMATION TECHNOLOGIES IN SOCIETY IT IS   (Switzerland)

^g NONE   (France)

Author keywords

27.12 MHz; hepatocellular carcinoma; phase II study; radiofrequency electromagnetic fields; tumour specific modulation frequencies

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DEATH; ELECTROMAGNETIC FIELD; FEMALE; HUMAN; IMAGING; LIVER CELL CARCINOMA; MALE; OUTPATIENT CARE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAFETY;

EID: 80052032302     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.292     Document Type: Article

References (34)

1. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De GJ, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(26): 4293-4300 (Pubitemid 46630787)
2. Amato D, Pasche B (1993) An evaluation of the safety of low energy emission therapy (published erratum appears in Compr Ther 1994;20(12):681. Compr Ther 19: 242-247
3. Barbault A, Costa F, Bottger B, Munden R, Bomholt F, Kuster N, Pasche B (2009) Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. J Exp Clin Cancer Res 28(1): 51
4. Boige V, Raoul JL, Pignon JP, Bouche O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M (2007) Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 97(7): 862-867 (Pubitemid 47519302)
5. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5): 1208-1236 (Pubitemid 43112690)
6. Cance WG, Stewart AK, Menck HR (2000) The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996. Cancer 88(4): 912-920 (Pubitemid 30091112)
7. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27(3): 446-452
8. Chang I (2003) Finite element analysis of hepatic radiofrequency ablation probes using temperature-dependent electrical conductivity. Biomed Eng Online 2: 12
9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1): 25-34
10. Choi BI (2007) Doppler and harmonic ultrasound for hepatocellular carcinoma. Hepatol Res 37(Suppl 2): S172-S177
11. Chuah B, Lim R, Boyer M, Ong AB, Wong SW, Kong HL, Millward M, Clarke S, Goh BC (2007) Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta Oncol 46(2): 234-238
12. Cohn AL, Myers JW, Mamus S, Deur C, Nicol S, Hood K, Khan MM, Ilegbodu D, Asmar L (2008) A phase II study of pemetrexed in patients with advanced hepatocellular carcinoma. Invest New Drugs 26(4): 381-386
13. Dollinger MM, Behrens CM, Lesske J, Behl S, Behrmann C, Fleig WE (2008) Thymostimulin in advanced hepatocellular carcinoma: a phase II trial. BMC Cancer 8: 72
14. ICNIRP (1998) Guidelines for limiting exposure to time-varying electric, magnetic and electromagnetic fields (up to 300 GHz). Health Phys 74: 494-522
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61(2): 69-90
16. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. Cancer J Clin 60(5): 277-300
17. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ (2004) Cancer statistics, 2004. Cancer J Clin 54(1): 8-29 (Pubitemid 38443417)
18. Kassianides C, Kew MC (1987) The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol Clin North Am 16(4): 553-562 (Pubitemid 18076292)
19. Kelly TL, Kripke DF, Hayduk R, Ryman D, Pasche B, Barbault A (1997) Bright light and LEET effects on circadian rhythms, sleep and cognitive performance. Stress Med 13: 251-258
20. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362(9399): 1907-1917 (Pubitemid 37518510)
21. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, for the Panel of Experts in HCC-Design Clinical Trials (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100(10): 698-711
22. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319): 1734-1739 (Pubitemid 34607087)
23. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, the SHARP Investigators Study Group (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378-390
24. Maruyama H, Yoshikawa M, Yokosuka O (2008) Current role of ultrasound for the management of hepatocellular carcinoma. World J Gastroenterol 14(11): 1710-1719 (Pubitemid 351493377)
25. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11): 693-700
26. Pasche B, Erman M, Hayduk R, Mitler M, Reite M, Higgs L, Dafni U, Amato D, Rossel C, Kuster N, Barbault A, Lebet JP (1996) Effects of low energy emission therapy in chronic psychophysiological insomnia. Sleep 19: 327-336 (Pubitemid 26000341)
27. Pasche B, Erman M, Mitler M (1990) Diagnosis and management of insomnia. N Engl J Med 323: 486-487
28. Pasche B, Barbault A (2003) Low-energy emission therapy: current status and future directions. In Bioelectromagnetic Medicine, Rosch PJ, Markov MS (eds) pp 321-327. Marcel Dekker Inc.: New York, NY
29. Reite M, Higgs L, Lebet JP, Barbault A, Rossel C, Kuster N, Dafni U, Amato D, Pasche B (1994) Sleep inducing effect of low energy emission therapy. Bioelectromagnetics 15: 67-75
30. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson III AB, Salem R (2009) Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 27(34): 5734-5742
31. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, Chen H, Clark-Garvey S, Weinberg A, Mandeli J, Christos P, Mazumdar M, Popa E, Brown RSJ, Rafii S, Schwartz JD (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocel-lular carcinoma. J Clin Oncol 26(18): 2992-2998
32. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10(1): 1-10 (Pubitemid 19099520)
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3): 205-216 (Pubitemid 30099779)
34. Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clin Oncol 23(13): 2892-2899 (Pubitemid 46224106)